Skip to main content
In stock|Targeted Therapy

Ruxolitinib

Oncology TypeHematologic (MPN)
Drug Class / MechanismJAK Inhibitor
No Image
Description

Ruxolitinib is classified as a JAK Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy
Oncology TypeHematologic (MPN)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3